Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Daniel A. Anaya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6569-3931; OpenAlex author ID A5102089067. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. The impact of neighborhood socioeconomic deprivation on metastatic pancreatic cancer treatment and survival: An incidence-based, causally-structured observatio… Co-author DOI 10.64898/2026.08.06.26359821↗
  2. Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma: Preoperative Planning, Technical Considerations, and Building a Program. First author DOI 10.1016/j.suc.2024.07.001↗
  3. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Last author DOI 10.1016/j.sopen.2023.02.001↗
  4. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Co-author DOI 10.1007/s00464-021-08845-9↗
  5. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Co-author DOI 10.1097/as9.0000000000000197↗
  6. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Co-author DOI 10.1097/sla.0000000000003706↗
  7. Outcome Disparities in Pancreatic Cancer: Need for Improved Regionalization of Care. Co-author DOI 10.1001/jamasurg.2015.4221↗
  8. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. First author DOI 10.1002/cncr.25763↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jason B. Fleming · 6 shared papers, 2021–2026 · strength 1.16
  2. Jason W. Denbo · 4 shared papers, 2022–2024 · strength 0.75
  3. Benjamin Daniel Powers · 4 shared papers, 2021–2026 · strength 0.69
  4. Jennifer B. Permuth · 4 shared papers, 2021–2026 · strength 0.69
  5. Mokenge Peter Malafa · 5 shared papers, 2016–2023 · strength 0.68
  6. José M. Pimiento · 4 shared papers, 2021–2023 · strength 0.56
  7. Pamela Joy Hodul · 4 shared papers, 2021–2023 · strength 0.56
  8. Justin A. Drake · 1 shared paper, 2024 · strength 0.31
  9. Dae Won Kim · 2 shared papers, 2022–2023 · strength 0.31
  10. Apurva Raghu · 1 shared paper, 2026 · strength 0.29
  11. Joon Kyung Kim · 2 shared papers, 2021–2023 · strength 0.27
  12. Kelvin Allenson · 1 shared paper, 2023 · strength 0.16
  13. David T. Pointer · 1 shared paper, 2022 · strength 0.15
  14. Samer A. Naffouje · 1 shared paper, 2022 · strength 0.15
  15. Dae Won Kim · 1 shared paper, 2022 · strength 0.13
  16. Luke Daniel Rothermel · 1 shared paper, 2021 · strength 0.11
  17. Danielle K. DePeralta · 1 shared paper, 2021 · strength 0.11
  18. Shaun P. McKenzie · 1 shared paper, 2011 · strength 0.03
  19. Avo Artinyan · 1 shared paper, 2011 · strength 0.03
  20. Joseph Kim · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.